Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CSL312 Autoinjector vs Needle Safety Device
NCT05306275Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of garadacimab in hereditary angioedema (HAE) (6 arms), sponsored by CSL Limited. Primary endpoints: Maximum plasma concentration and Area under the concentration-time curve from time 0 extrapolated to infinite time. Started Apr 2022; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05306275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306275.